Literature DB >> 1901073

Noninvasive detection of reperfusion in acute myocardial infarction based on plasma activity of creatine kinase MB subforms.

P R Puleo1, M B Perryman.   

Abstract

Successful thrombolytic therapy is associated with an accelerated release of creatine kinase (CK) MB from necrotic myocardium. With use of a previously validated assay, the plasma kinetics of the myocardial subform (MB2) and the plasma-modified subform (MB1) were determined in blood samples obtained from 56 patients with acute Q wave myocardial infarction: 33 patients who received thrombolytic therapy (group A) and 23 patients managed conservatively (group B). Plasma MB2 activity increased more rapidly in the group A patients, but there was substantial overlap with group B. Plasma MB1 activity did not differ significantly between the two groups. The MB2/MB1 ratio was significantly higher in group A patients than in group B patients between 2 and 10 h after the onset of infarction. Among group A patients, the ratio increased from 2.4 +/- 1.6 to 4.6 +/- 2.0 in the 1st h after therapy (p less than 0.001). The peak ratio was 6.3 +/- 2.5 in group A patients and 3.1 +/- 1.2 in group B patients. Twenty-seven of the 33 group A patients had a peak ratio greater than 3.8 versus 5 of the 23 group B patients (p less than 0.001). In seven group A patients, the ratio was greater than 3.8 before plasma CK MB activity was out of the normal range. Angiography was performed at 5.0 +/- 3.5 days in 39 patients. Eighteen (90%) of 20 patients with a patent infarct-related artery had a peak ratio greater than 3.8; 17 (89.5%) of 19 patients with an occluded infarct-related artery had a ratio less than 3.8 (p less than 0.001).(ABSTRACT TRUNCATED AT 250 WORDS)

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1901073     DOI: 10.1016/0735-1097(91)90828-w

Source DB:  PubMed          Journal:  J Am Coll Cardiol        ISSN: 0735-1097            Impact factor:   24.094


  5 in total

1.  ECG monitoring, biochemical Testing, and Anticoagulation Assessment.

Authors: 
Journal:  J Thromb Thrombolysis       Date:  1996       Impact factor: 2.300

2.  Current status of thrombolytic therapy in acute myocardial infarction.

Authors:  B Stein; R Roberts
Journal:  Tex Heart Inst J       Date:  1991

3.  Early, Complete Infarct Vessel Patency: Arriving at a Gold Standard for Future Clinical Investigation in Myocardial Reperfusion.

Authors: 
Journal:  J Thromb Thrombolysis       Date:  1997       Impact factor: 2.300

4.  Defibrotide versus heparin in the prevention of coronary reocclusion after thrombolysis in acute myocardial infarction.

Authors:  M Tubaro; G Mattioli; F Matta; C Cappello; E Natale; R Ricci; P Gerardi; F Milazzotto
Journal:  Cardiovasc Drugs Ther       Date:  1993-11       Impact factor: 3.727

5.  Methods of creatine kinase-MB analysis to predict mortality in patients with myocardial infarction treated with reperfusion therapy.

Authors:  Renato D Lopes; Yuliya Lokhnygina; Victor Hasselblad; Kristin L Newby; Eric Yow; Christopher B Granger; Paul W Armstrong; Judith S Hochman; James S Mills; Witold Ruzyllo; Kenneth W Mahaffey
Journal:  Trials       Date:  2013-05-02       Impact factor: 2.279

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.